OncoMatch/Clinical Trials/NCT06228079
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Is NCT06228079 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Immunotherapy,Toripalimab and Chemotherapy,Gemcitabine based regimen for recurrent nasopharyngeal carcinoma.
Treatment: Immunotherapy,Toripalimab · Chemotherapy,Gemcitabine based regimen — Adjuvant Therapy Versus Endoscopic Surgery Alone in Early-stage Recurrent Nasopharyngeal Carcinoma: A Multicenter Randomized Controlled Trial
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage RT1, RT2, RT3
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: radiation therapy
previously radiotherapy for only 1 course
Must have received: surgery
Undergone endoscopic surgery with negative pathological margin
Cannot have received: radioactive particle planting
History of radioactive particle planting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06228079 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radioactive particle planting disqualifies patients from enrollment.
What disease stage is eligible?
Stage RT1 or RT2 or RT3 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages